Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

53.03 -2.94 (-5.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,025,569
Open 55.76
Bid (Size) 52.55 (100)
Ask (Size) 54.06 (300)
Prev. Close 55.97
Today's Range 52.79 - 56.18
52wk Range 33.76 - 57.57
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead ↗
They are riding strong tailwinds that could lift them higher. 
Via The Motley Fool
Topics Economy
News headline image
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
From Exelixis, Inc.
Via Business Wire

Performance

YTD
+21.7%
+21.7%
1 Month
-2.5%
-2.5%
3 Month
+19.3%
+19.3%
6 Month
+25.4%
+25.4%
1 Year
+43.9%
+43.9%

More News

Read More
News headline image
3 Under-the-Radar Stocks to Buy and Hold ↗
Via The Motley Fool
Exelixis Inc. (NASDAQ:EXEL): A Decent Value Play in the Biotechnology Sector ↗
Via Chartmill
Exelixis Inc (NASDAQ:EXEL) Offers Decent Value with Strong Profitability and Financial Health ↗
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) Presents a Compelling Case for Value Investors ↗
Via Chartmill
Exelixis Beats Q1 Estimates and Advances Pipeline, Driving EXEL Momentum ↗
Via Chartmill
News headline image
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
From Exelixis, Inc.
Via Business Wire
Exelixis Inc (NASDAQ:EXEL) Passes the Caviar Cruise Quality Screen with Zero Debt and 54% ROIC ↗
Via Chartmill
Exelixis Inc. (NASDAQ:EXEL) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near ↗
Via MarketBeat
News headline image
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
From Exelixis, Inc.
Via Business Wire
News headline image
GlobeFlex Exits NCR Atleos After Brink’s Buyout Deal ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
Prediction: This Stock Could Double By 2031 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis (EXEL) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026
From Exelixis, Inc.
Via Business Wire
News headline image
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist ↗
Via The Motley Fool
News headline image
Exelixis: A Strong Contender in the Cancer Drug Market ↗
Via The Motley Fool
News headline image
The Best Healthcare Stocks to Buy With $50 Right Now ↗
Via The Motley Fool

Frequently Asked Questions

Is Exelixis, Inc. - Common Stock publicly traded?
Yes, Exelixis, Inc. - Common Stock is publicly traded.
What exchange does Exelixis, Inc. - Common Stock trade on?
Exelixis, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Exelixis, Inc. - Common Stock?
The ticker symbol for Exelixis, Inc. - Common Stock is EXEL on the Nasdaq Stock Market
What is the current price of Exelixis, Inc. - Common Stock?
The current price of Exelixis, Inc. - Common Stock is 53.03
When was Exelixis, Inc. - Common Stock last traded?
The last trade of Exelixis, Inc. - Common Stock was at 07/31/26 04:00 PM ET
What is the market capitalization of Exelixis, Inc. - Common Stock?
The market capitalization of Exelixis, Inc. - Common Stock is 16.71B
How many shares of Exelixis, Inc. - Common Stock are outstanding?
Exelixis, Inc. - Common Stock has 17B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.